Cargando…
Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
BACKGROUND: Anlotinib showed significant survival benefits in advanced non‐small cell lung cancer (NSCLC) patients as a third‐ or further‐line treatment in the ALTER0303 trial. We aimed to evaluate the efficacy of anlotinib in patients with different histologies. METHODS: The ALTER0303 trial was a r...
Autores principales: | Cheng, Ying, Han, Baohui, Li, Kai, Wang, Qiming, Zhang, Li, Shi, Jianhua, Wang, Zhehai, He, Jianxing, Shi, Yuankai, Chen, Weiqiang, Wang, Xiuwen, Luo, Yi, Nan, Kejun, Jin, Faguang, Li, Baolan, Zhu, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163095/ https://www.ncbi.nlm.nih.gov/pubmed/32064794 http://dx.doi.org/10.1002/cam4.2913 |
Ejemplares similares
-
The efficacy of anlotinib as third-line treatment for non-small cell lung cancer by EGFR mutation status: a subgroup analysis of the ALTER0303 randomized phase 3 study
por: Zhao, Yizhuo, et al.
Publicado: (2022) -
Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial
por: Shi, Jianhua, et al.
Publicado: (2021) -
Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
por: Si, Xiaoyan, et al.
Publicado: (2019) -
Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018) -
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
por: Han, Baohui, et al.
Publicado: (2018)